Last reviewed · How we verify
Buffered acetylsalicylic acid
At a glance
| Generic name | Buffered acetylsalicylic acid |
|---|---|
| Also known as | Bufferin Combination Tablet A81 |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (PHASE1)
- Comparison of Effects of Buffered and Enteric-coated Forms of Aspirin on Platelet Aggregation in Patients With Diabetes Mellitus and Chronic Coronary Syndrome
- Alleviation of Common Cold Symptoms (PHASE1)
- Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction (PHASE1, PHASE2)
- Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan (NA)
- Assessment of The Effect of Apixaban in AF
- Platelet Hyperreactivity to Aspirin and Stroke (PHASE4)
- Study to Assess the Bioequivalence Between D961S and Esomeprazole/Buffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |